Topical Fisionerv® is effective in treatment of peripheral neuropathic pain

Topical Fisionerv® is effective in treatment of peripheral neuropathic pain

Authors

  • Angelo Tarullo Dept. of Biomedical Sciences and Human Oncology, School of Medicine, University of Bari, Italy.
  • Antonella Tarullo Dept. of Biomedical Sciences and Human Oncology, School of Medicine, University of Bari, Italy.
  • Emanuela Lacatena SOU Physiatry "N. Melli", S. Pietro V.co, ASL-BR, Brindisi, Italy
  • Luigi Santacroce Ionian Dept, Medical School, University of Bari, Italy
  • Angelo Michele Inchingolo
  • Giuseppina Malcangi School of Medicine, University of Bari, Italy.
  • Salvatore Scacco Dept. of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari, Italy
  • Margherita Fanelli Dept. of Biomedical Sciences and Human Oncology, School of Medicine, University of Bari, Italy.
  • Raffaele Cagiano Dept. of Biomedical Sciences and Human Oncology, School of Medicine, University of Bari, Italy.
  • Francesco Inchingolo Dept of Interdisciplinary Medicine, University of Bari, Italy
  • Monica Caprio Dept. of Biomedical Sciences and Human Oncology, School of Medicine, University of Bari, Italy.
  • Gianna Dipalma School of Medicine, University of Bari, Italy.
  • Andrea Ballini Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari “Aldo Moro”, Italy
  • Antonietta Clemente Dept. of Biomedical Sciences and Human Oncology, School of Medicine, University of Bari, Italy
  • Alessio Danilo Inchingolo School of Medicine, University of Bari, Italy.
  • Francesco Girolamo Dept. of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari, Italy
  • Maria Tattoli Dept. of Biomedical Sciences and Human Oncology, School of Medicine, University of Bari, Italy.

Keywords:

peripheral neuropathies, fisionerv ®” emulgel, physiatric treatment, neuropatic pain

Abstract

Background: Management of neuropathic pain (Neu P) is complex and difficult. Although there are several therapeutic options, treatment with Neu P is often inadequate, which led to undertreated patients. Thus, it would be desirable, for Neu P treatment, further multimechanistics approaches. Objective: The aim of the present study was to evaluate, in Neu P management, the effectiveness of “FISIONERV, a gel for topical use. Setting: This study was conducted in the “Rehabilitation Unit of N. Melli’s Hospital, Brindisi, Italy”. Patients and intervention: In this study a double- blind randomized controlled clinical trial was conducted over 8-week treatment on 58 outpatients affected by Neu P caused by lumbar sciatica or lumbar disk herniation and/or lumbar canal stenosis (31 subjects), or with carpal tunnel syndrome (27 subjects), randomly assigned to the following two groups: Group A; n=29, received (fisionerv® gel, 3 times/day) added to physiotherapy (forty minutes-daily session). Group B; n=29 received a vehicle gel (placebo, 3 times/day) added to physiotherapy (forty minutes-daily session). Measurements: Pain was assessed by a visual analogue scale (VAS). Neuropathic symptoms frequency (pain, burning, paraesthesiae and numbness) were scored at baseline and at the end of the treatment. Treatment compliance and safety were also evaluated. Results: Both groups experienced a significant reduction in VAS and neuropathic symptoms after 8-treatment weeks. However, a significant (p<0.05) improvement was observed in group A (VAS mean 5.3 (1.10) with respect to group B (VAS mean=6.17 (0.80), already after 4 weeks of treatment. A further VAS reduction was recorded at 8 treatment weeks, with significant difference between the treatments (group A: VAS mean=1.89 (0.77); group B: VAS mean=3.79 (1.20) (p<0.001). In addition, more patients of the group A, than in group B, reported an improvement of their neurophatc pain (p<0.01). No adverse drug reaction was observed. Conclusion: Use of fisionerv®, in combination with physiotherapy, resulted a useful approach to NP treatment. Clinical rehabilitation impact: These preliminary observations suggest that some interesting goals (better pain control and physical wellbeing) could be achieved by a multimodal therapy in NP patients. 

Author Biography

Raffaele Cagiano, Dept. of Biomedical Sciences and Human Oncology, School of Medicine, University of Bari, Italy.

Dipartimento di SCIENZE BIOMEDICHE ed ONCOLOGIA UMANA

Downloads

Published

24-01-2019

Issue

Section

ORIGINAL ARTICLES

How to Cite

1.
Topical Fisionerv® is effective in treatment of peripheral neuropathic pain. Acta Biomed [Internet]. 2019 Jan. 24 [cited 2024 Apr. 22];90(1):51-5. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/6305

Most read articles by the same author(s)